Cantor Fitzgerald Weighs in on ARTV FY2026 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($2.14) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.15).

ARTV has been the subject of a number of other research reports. HC Wainwright upgraded Artiva Biotherapeutics to a "buy" rating and set a $12.00 price objective for the company in a report on Wednesday. Needham & Company LLC dropped their price target on Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, Wedbush reissued an "outperform" rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $17.80.

Artiva Biotherapeutics Stock Up 7.7%

Shares of ARTV stock traded up $0.15 during midday trading on Wednesday, reaching $2.11. 79,828 shares of the stock were exchanged, compared to its average volume of 169,288. Artiva Biotherapeutics has a 1 year low of $1.78 and a 1 year high of $17.31. The company's 50 day moving average is $2.14 and its two-hundred day moving average is $5.38.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in Artiva Biotherapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company's stock worth $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Artiva Biotherapeutics by 3.8% in the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company's stock worth $1,180,000 after purchasing an additional 4,335 shares during the period. Charles Schwab Investment Management Inc. grew its position in Artiva Biotherapeutics by 26.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock valued at $165,000 after buying an additional 11,355 shares during the period. Nuveen LLC bought a new position in Artiva Biotherapeutics in the first quarter worth approximately $144,000. Finally, JPMorgan Chase & Co. grew its position in shares of Artiva Biotherapeutics by 250.7% during the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company's stock valued at $379,000 after acquiring an additional 26,893 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.